|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohka F, Natsume A and Wakabayashi T:
Current trends in targeted therapies for glioblastoma multiforme.
Neurol Res Int. 2012:8784252012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Natsume A, Ishii D, Wakabayashi T, Tsuno
T, Hatano H, Mizuno M and Yoshida J: IFN-beta down-regulates the
expression of DNA repair gene MGMT and sensitizes resistant glioma
cells to temozolomide. Cancer Res. 65:7573–7579. 2005.PubMed/NCBI
|
|
5
|
Natsume A, Wakabayashi T, Ishii D, Maruta
H, Fujii M, Shimato S, Ito M and Yoshida J: A combination of
IFN-beta and temozolomide in human glioma xenograft models:
Implication of p53-mediated MGMT downregulation. Cancer Chemother
Pharmacol. 61:653–659. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wakabayashi T, Kayama T, Nishikawa R, et
al: A multicenter phase I trial of combination therapy with
interferon-β and temozolomide for high-grade gliomas (INTEGRA
study): The final report. J Neurooncol. 104:573–577. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motomura K, Natsume A, Kishida Y, Higashi
H, Kondo Y, Nakasu Y, Abe T, Namba H, Wakai K and Wakabayashi T:
Benefits of interferon-β and temozolomide combination therapy for
newly diagnosed primary glioblastoma with the unmethylated MGMT
promoter: A multicenter study. Cancer. 117:1721–1730. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fujimaki T, Ishii H, Matsuno A, Arai H and
Nakagomi T: Effectiveness of interferon-beta and temozolomide
combination therapy against temozolomide-refractory recurrent
anaplastic astrocytoma. World J Surg Oncol. 5:892007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park JA, Joe YA, Kim TG and Hong YK:
Potentiation of antiglioma effect with combined temozolomide and
interferon-β. Oncol Rep. 16:1253–1260. 2006.PubMed/NCBI
|
|
10
|
Felsberg J, Thon N, Eigenbrod S, et al:
German Glioma Network: Promoter methylation and expression of MGMT
and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in
paired primary and recurrent glioblastomas. Int J Cancer.
129:659–670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johannessen TC and Bjerkvig R: Molecular
mechanisms of temozolomide resistance in glioblastoma multiforme.
Expert Rev Anticancer Ther. 12:635–642. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saito R, Mizuno M, Hatano M, Kumabe T,
Yoshimoto T and Yoshida J: Two different mechanisms of apoptosis
resistance observed in interferon-beta induced apoptosis of human
glioma cells. J Neurooncol. 67:273–280. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hong YK, Chung DS, Joe YA, Yang YJ, Kim
KM, Park YS, Yung WK and Kang JK: Efficient inhibition of in vivo
human malignant glioma growth and angiogenesis by interferon-beta
treatment at early stage of tumor development. Clin Cancer Res.
6:3354–3360. 2000.PubMed/NCBI
|
|
14
|
Yuki K, Natsume A, Yokoyama H, Kondo Y,
Ohno M, Kato T, Chansakul P, Ito M, Kim SU and Wakabayashi T:
Induction of oligodendrogenesis in glioblastoma-initiating cells by
IFN-mediated activation of STAT3 signaling. Cancer Lett. 284:71–79.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Happold C, Roth P, Silginer M, Florea AM,
Lamszus K, Frei K, Deenen R, Reifenberger G and Weller M:
Interferon-β induces loss of spherogenicity and overcomes therapy
resistance of glioblastoma stem cells. Mol Cancer Ther. 13:948–961.
2014. View Article : Google Scholar : PubMed/NCBI
|
